Compare ORC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORC | HROW |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2013 | N/A |
| Metric | ORC | HROW |
|---|---|---|
| Price | $7.18 | $46.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | N/A | ★ $68.86 |
| AVG Volume (30 Days) | ★ 5.6M | 535.4K |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | ★ 20.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | $80,187,000.00 | ★ $250,042,000.00 |
| Revenue This Year | $82.99 | $39.05 |
| Revenue Next Year | $61.79 | $40.48 |
| P/E Ratio | $12.43 | ★ N/A |
| Revenue Growth | 5.93 | ★ 47.83 |
| 52 Week Low | $5.69 | $20.85 |
| 52 Week High | $9.01 | $51.30 |
| Indicator | ORC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 57.15 |
| Support Level | $7.09 | $44.48 |
| Resistance Level | $7.41 | $51.30 |
| Average True Range (ATR) | 0.10 | 2.50 |
| MACD | -0.01 | 0.50 |
| Stochastic Oscillator | 26.98 | 58.37 |
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.